Corcept Therapeutics
CORT
$91.88
-1.47%
Corcept Therapeutics is a commercial-stage pharmaceutical company focused on developing drugs that modulate the cortisol hormone to treat severe metabolic, oncologic, and neuropsychiatric disorders, with its marketed product Korlym (mifepristone) for Cushing's syndrome. The company holds a unique position as the only approved therapy for hypercortisolism, giving it a niche but defensible market leadership. Investor attention is currently centered on the recent FDA approval of its new cancer drug Lifyorli, which expands its pipeline beyond Cushing's and has driven significant stock appreciation, while debates continue around the sustainability of its growth and the competitive landscape for its pipeline candidates.…
CORT
Corcept Therapeutics
$91.88
Related headlines
Investment Opinion: Should I buy CORT Today?
Rating: Hold. The thesis is that Corcept's recent FDA approval of Lifyorli provides a new growth catalyst, but the current valuation already prices in significant success, leaving limited upside given the decelerating core business and margin pressure. The analyst consensus is Buy, but with only 2 analysts, the average target price implied by the estimated EPS of $12.28 at 36.6x P/E suggests a target of ~$449, which appears unrealistic and may reflect data errors. Supporting evidence: Revenue grew 11.1% YoY in Q4 2025, but operating margin collapsed to 2.2% from 13.9% a year ago. The P/E of 36.6x is a 66% premium to the industry average of 22x. Free cash flow of $141.8 million TTM is positive, but the PEG ratio is negative (-1.24), indicating expected earnings decline. The stock has already surged 119% in three months, pricing in the Lifyorli approval. Risks & Conditions: The biggest risks are that Lifyorli revenue disappoints or that operating margins continue to compress. This Hold would upgrade to Buy if the P/E compresses below 25x or if Lifyorli shows strong early sales, and downgrade to Sell if revenue growth decelerates below 5% or margins turn negative. Valuation verdict: The stock is overvalued relative to its history and peers, trading at a premium that requires flawless execution.
Sign up to view all
CORT 12-Month Price Forecast
Corcept's outlook is balanced between the bullish catalyst of Lifyorli approval and the bearish headwinds of decelerating growth and margin compression. The base case of 50% probability reflects a scenario where Lifyorli contributes modestly but does not transform the financials, keeping the stock range-bound. The bull case (25%) requires rapid adoption and margin recovery, while the bear case (25%) hinges on commercial failure. The neutral stance with medium confidence reflects the uncertainty around Lifyorli's trajectory and the stock's elevated valuation. An upgrade to bullish would require evidence of accelerating revenue and margin expansion; a downgrade to bearish would follow disappointing Lifyorli sales or further margin erosion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corcept Therapeutics's 12-month outlook, with a consensus price target around $119.44 and implied upside of +30.0% versus the current price.
Average Target
$119.44
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$74 - $119
Analyst target range
Corcept has only 2 analysts covering the stock, which is limited for a company of its market cap (~$3.6 billion). Both analysts rate the stock a Buy, with no Hold or Sell ratings, indicating a uniformly bullish consensus. The average target price is not explicitly provided in the data, but the estimated EPS average is $12.28, which at the current P/E of 36.6x would imply a target price of approximately $449, suggesting massive upside. However, this seems unrealistic and may reflect a data error or forward estimates that are not directly comparable. Given the limited coverage, the implied upside from the average target is not calculable with confidence. The low target EPS is $10.13 and the high is $15.47, indicating a wide range of expectations. The high target likely assumes successful commercialization of Lifyorli and pipeline progress, while the low target may reflect concerns about competition or slower adoption. The limited analyst coverage means the stock may be underfollowed, leading to less efficient price discovery and potentially higher volatility. The recent ratings from HC Wainwright and Canaccord Genuity have been consistently Buy, with no downgrades, reinforcing the bullish sentiment. However, with only two analysts, the consensus is fragile and could shift quickly with new data.
Drowning in data?
Find the real signal!
Bulls vs Bears: CORT Investment Factors
Corcept presents a compelling bull case driven by its recent FDA approval of Lifyorli, fortress balance sheet, and exceptional gross margins. The stock has surged 119% in three months on this catalyst, and the zero-debt balance sheet provides a safety net. However, the bear case highlights decelerating revenue growth, margin compression, and a stretched valuation at 36.6x P/E versus the industry average of 22x. The single most important tension is whether Lifyorli can reignite revenue growth and margin expansion, or whether rising costs and competition will erode profitability. Currently, the bull case has stronger evidence given the recent approval and strong technical momentum, but the valuation leaves little room for error.
Bullish
- FDA Approval of Lifyorli Expands Pipeline: The recent FDA approval of Lifyorli provides a second commercial product, reducing reliance on Korlym and opening a new growth avenue in oncology. This catalyst drove the stock nearly 9% higher in a single week and underpins the 119% surge over the past three months.
- Fortress Balance Sheet with Zero Debt: Corcept has a debt-to-equity ratio of 0.009 and a current ratio of 2.92, indicating ample liquidity and minimal financial risk. Free cash flow of $141.8 million TTM provides internal funding for R&D and commercialization without dilution.
- High Gross Margins Reflecting Pricing Power: Gross margins of 98.7% in Q4 2025 demonstrate strong pricing power for its branded Cushing's therapy. This is well above the biotech industry average and provides a cushion for operating expenses.
- Strong Momentum Near 52-Week High: The stock is trading at $91.88, 96.6% of its 52-week high of $95.11, with exceptional relative strength of 108.1% over 3 months versus the S&P 500. This technical strength reflects investor optimism about the Lifyorli launch.
Bearish
- Decelerating Revenue Growth and Thin Margins: Q4 2025 revenue grew only 11.1% YoY, down from 25.6% in Q3 2024, and operating margin collapsed to 2.2% from 13.9% a year earlier due to rising SG&A and R&D costs. This suggests the core business is maturing while expenses escalate.
- Elevated Valuation vs. Industry Peers: The trailing P/E of 36.6x is a 66% premium to the biotech industry average of 22x. The PEG ratio is negative (-1.24) due to expected earnings decline, indicating the current multiple may not be justified by near-term growth.
- Limited Analyst Coverage and Low Liquidity: Only 2 analysts cover the stock, making the consensus fragile and price discovery inefficient. The short ratio of 8.55 days suggests elevated short interest, reflecting skepticism about the sustainability of the rally.
- Dependence on Korlym and Pipeline Uncertainty: Korlym remains the primary revenue driver, and while Lifyorli is approved, its commercial success is unproven. The sequential revenue decline from Q3 to Q4 2025 ($207.6M to $202.1M) raises concerns about market saturation.
CORT Technical Analysis
Corcept is in a powerful sustained uptrend, with the stock up 27.6% over the past year and currently trading at $91.88, which is 96.6% of its 52-week range (high $95.11, low $28.66). This positioning near the 52-week high reflects strong bullish momentum and investor optimism, though it also raises the risk of overextension and potential profit-taking. The stock has more than doubled from its 52-week low, indicating a robust recovery and trend acceleration. Over the past three months, the stock has surged 119.2%, and over the past month it has gained 17.6%, showing accelerating short-term momentum that aligns with the longer-term uptrend. This consistent strength across time frames suggests a powerful trend driven by fundamental catalysts, with no signs of divergence or deceleration. The relative strength versus the S&P 500 is exceptional, with 3-month relative strength of 108.1% and 1-month relative strength of 13.5%, confirming the stock is leading the market. The 52-week high of $95.11 serves as immediate resistance; a breakout above this level would signal a continuation of the uptrend and likely attract further buying. Support lies at the 52-week low of $28.66, though the more relevant near-term support is around $70, the level from which the stock accelerated in June. With a beta of 0.46, Corcept is significantly less volatile than the market, which is unusual for a biotech stock and suggests the stock's moves are driven more by company-specific catalysts than broad market swings. This low beta implies that the recent rally is fundamentally driven and may be more sustainable, but also means the stock may not participate as strongly in a broad market rally.
Beta
0.46
0.46x market volatility
Max Drawdown
-64.4%
Largest decline past year
52-Week Range
$29-$95
Price range past year
Annual Return
+27.6%
Cumulative gain past year
| Period | CORT Return | S&P 500 |
|---|---|---|
| 1m | +17.6% | +1.8% |
| 3m | +119.2% | +10.0% |
| 6m | +145.0% | +8.8% |
| 1y | +27.6% | +21.1% |
| ytd | +140.5% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CORT Fundamental Analysis
Corcept's revenue trajectory is solidly growing, with Q4 2025 revenue of $202.1 million representing 11.1% year-over-year growth. However, the growth rate has decelerated from the 25.6% YoY growth seen in Q3 2024, and revenue sequentially declined from Q3 2025's $207.6 million. The company's top line is heavily dependent on Korlym sales, and while the recent FDA approval of Lifyorli provides a new growth driver, the near-term revenue trend shows a maturation of the Cushing's franchise. The company is profitable, with Q4 2025 net income of $24.3 million and a net margin of 12.0%. Gross margins are exceptionally high at 98.7%, typical for a specialty pharmaceutical company with a branded product. However, operating margins are thin at 2.2% in Q4 2025, down from 13.9% in Q4 2024, due to rising SG&A and R&D expenses as the company invests in its pipeline. The trajectory toward profitability is positive, but margin compression is a concern if revenue growth does not accelerate. Corcept has a fortress balance sheet with zero debt (debt-to-equity of 0.009) and a current ratio of 2.92, indicating ample liquidity. Free cash flow for the trailing twelve months is $141.8 million, providing strong internal funding for R&D and commercialization. Return on equity is 15.4%, reflecting efficient capital use, though the company does not pay a dividend, instead reinvesting in growth. The strong cash position and lack of debt minimize financial risk, but the heavy reliance on operating cash flow to fund pipeline expansion means any revenue shortfall could pressure investment.
Quarterly Revenue
$202125000.0B
2025-12
Revenue YoY Growth
+11.12%
YoY Comparison
Gross Margin
98.74%
Latest Quarter
Free Cash Flow
$141785000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CORT Overvalued?
Since Corcept is profitable with net income of $24.3 million in Q4 2025, the primary valuation metric is the P/E ratio. The trailing P/E is 36.6x, while the forward P/E is 36.8x, indicating that the market expects earnings to remain relatively stable. The minimal gap between trailing and forward multiples suggests limited growth expectations are priced in, which may be conservative given the recent FDA approval. Compared to the biotechnology industry average P/E of approximately 22x, Corcept trades at a 66% premium. This premium is partially justified by its high gross margins (98.7%) and profitability, but the premium is stretched given the decelerating revenue growth and thin operating margins. The stock's P/S ratio of 4.75x is also elevated versus the industry average of around 3x, reflecting the market's willingness to pay for its revenue stream. Historically, Corcept's trailing P/E has ranged from 17.6x to 146.5x over the past five years. The current 36.6x is near the lower end of this range, suggesting that despite the recent rally, the stock is not historically overvalued on an earnings basis. However, the P/E was as low as 17.6x in late 2021, so the current level still implies a premium to historical troughs. The PEG ratio is negative (-1.24) due to negative earnings growth expectations, which is a red flag and suggests that the current P/E may not be supported by near-term earnings momentum.
PE
36.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~147x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
51.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Corcept's operating margin fell from 13.9% in Q4 2024 to 2.2% in Q4 2025, a dramatic compression driven by a 56% increase in SG&A expenses to $130.2 million. While the company has zero debt, its reliance on operating cash flow to fund R&D means any revenue shortfall could force spending cuts or dilution. The sequential revenue decline from Q3 to Q4 2025 ($207.6M to $202.1M) suggests the core Cushing's franchise may be maturing, increasing pressure on Lifyorli to deliver growth. Market & Competitive Risks: The stock trades at a 66% premium to the biotech industry average P/E, making it vulnerable to multiple compression if growth disappoints. With a beta of 0.46, the stock is less correlated to the market, but its low liquidity (short ratio of 8.55 days) could amplify downside moves. The recent approval of Lifyorli faces competition from existing oncology therapies, and any clinical setbacks in the pipeline (relacorilant, dazucorilant) could derail sentiment. Worst-Case Scenario: If Lifyorli fails to gain traction and Korlym sales continue to decelerate, the stock could retest its 52-week low of $28.66, representing a 68.8% decline from the current price of $91.88. This scenario would likely involve margin erosion, analyst downgrades, and a loss of investor confidence, with the historical max drawdown of -64.4% providing a precedent for severe downside.
FAQ
The key risks are: 1) Commercial risk: Lifyorli may fail to achieve expected sales, given competition in oncology and the company's limited commercial experience beyond Cushing's. 2) Margin compression: Operating margins fell from 13.9% to 2.2% in one year, and further deterioration could lead to losses. 3) Valuation risk: The P/E of 36.6x is a 66% premium to the industry, making the stock vulnerable to multiple compression if growth disappoints. 4) Limited coverage: With only 2 analysts, the stock is underfollowed, leading to potential volatility and inefficient pricing. The most severe risk is a 68.8% decline to the 52-week low of $28.66 if Lifyorli fails.
The 12-month forecast is mixed, with a base case (50% probability) of the stock trading between $70 and $95, reflecting modest Lifyorli adoption and stable Korlym sales. The bull case (25% probability) targets $95-$120 if Lifyorli exceeds expectations and margins improve. The bear case (25% probability) sees the stock falling to $29-$50 if Lifyorli disappoints and Korlym declines. The most likely scenario is the base case, where the stock remains range-bound as the market waits for tangible evidence of Lifyorli's commercial success. The current price of $91.88 is near the top of the base case range, suggesting limited upside in the near term.
Corcept appears overvalued relative to its peers and its own growth trajectory. The trailing P/E of 36.6x is 66% above the biotech industry average of 22x. The PEG ratio is negative (-1.24) due to expected earnings decline, suggesting the current multiple is not supported by near-term growth. Historically, the P/E has ranged from 17.6x to 146.5x over five years, and the current level is near the lower end, but the decelerating revenue growth (11.1% YoY) and margin compression (operating margin down to 2.2%) argue for a lower multiple. The market is pricing in optimism about Lifyorli, but the valuation leaves little room for disappointment.
Corcept is a speculative buy for investors with a high risk tolerance who believe in the commercial success of Lifyorli. The stock has surged 119% in three months on the approval news, and the current P/E of 36.6x is a 66% premium to the biotech industry average. The analyst consensus is Buy, but with only 2 analysts, the coverage is thin. The biggest downside risk is that Lifyorli fails to gain traction, which could send the stock back toward its 52-week low of $28.66. For long-term investors, the zero-debt balance sheet and high gross margins provide a safety net, but the near-term risk/reward is balanced. It is not a good buy for conservative investors seeking stable returns.
Corcept is better suited for long-term investment given its low beta of 0.46, zero-debt balance sheet, and potential for pipeline-driven growth. The stock's high short ratio (8.55 days) and recent 119% surge in three months suggest short-term volatility, but the fundamental story hinges on Lifyorli's adoption over the next 1-2 years. Short-term traders may profit from momentum, but the risk of a pullback is significant. A minimum holding period of 12-18 months is recommended to allow Lifyorli to demonstrate its commercial potential. The company does not pay a dividend, so returns depend entirely on price appreciation.
